By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Zymeworks 

540 – 1385 West 8th Avenue

Vancouver  British Columbia  V6H 3V9  Canada
Phone: 604-678-1388 Fax: 604-737-7077


SEARCH JOBS

Established in 2003 with offices in Vancouver, BC and Seattle, WA, Zymeworks is a fast-growing, clinical-stage biotechnology company dedicated to the research, development and commercialization of best-in-class therapeutic bispecific antibodies and antibody drug conjugates for the treatment of cancer and autoimmune diseases. Zymeworks is proud to have active collaborations with Merck, Eli Lilly, Celgene, GlaxoSmithKline, and Daiichi-Sankyo is committed to making a meaningful difference in the lives of patients everywhere.

Zymeworks has received multiple Canadian awards for innovation including British Columbia’s “Emerging Life Sciences Company of the Year” in 2013 and BIOTECanada’s “Gold Leaf Emerging Company of the Year” award in 2015. Most recently, Zymeworks was named the “Life Sciences Company of the Year” for 2016 by LifeSciences BC, and was the recipient of BIOTECanada’s “Gold Leaf Biotech Company of the Year” award in 2016.


Key Statistics


Email: info@zymeworks.com
Ownership: Private

Web Site: Zymeworks
Employees:
Symbol: 
 









Company News
Zymeworks Reports Second Quarter 2017 Financial Results 8/9/2017 7:37:33 AM
Zymeworks To Present At 37th Annual Canaccord Genuity Growth Conference 8/7/2017 6:52:13 AM
Zymeworks Appoints Dr. Natalie Sacks To Its Board Of Directors 8/3/2017 7:25:53 AM
Zymeworks To Host Second Quarter 2017 Financial Results Conference Call On August 8, 2017 8/2/2017 6:37:26 AM
Zymeworks And Daiichi Sankyo Announce Successful Achievement Of A Research Milestone In Bispecific Antibody Collaboration 7/18/2017 7:33:21 AM
Drug Candidates Developed Using Zymeworks’ Azymetric Platform Nominated For Late-Stage, Preclinical Development By Eli Lilly (LLY) 6/12/2017 8:09:15 AM
Zymeworks Presents Safety And Anti-Tumor Activity Data From The Ongoing Phase I Study Of ZW25 At ASCO Annual Meeting (ASCO 2017) 6/5/2017 8:22:36 AM
Zymeworks Announces Closing Of Partial Exercise Of Over-Allotment Option For Its Initial Public Offering 5/31/2017 8:41:38 AM
Vancouver’s Zymeworks to Hire an Additional 45 Employees by the End of 2017 5/31/2017 7:00:10 AM
Zymeworks Announces Partial Exercise Of Over-Allotment Option For Its Initial Public Offering 5/26/2017 8:26:00 AM
123456
//-->